June 22, 2026
Proteome Sciences plc (AIM:PRM) is pleased to announce that the Company has secured a further significant clinical contract connected to its target engagement/chemoproteomics platform. The Company anticipates this contract being a precursor to a new clinical trial programme that will be initiated later in 2026.